Strategic partnerships CUTISS has a strong track record of strategic collaborations with industrial automation leaders like Tecan to scale automated skin manufacturing, presenting a clear pathway for co-development, tooling, and contract manufacturing opportunities.

Clinical readiness With denovoSkin in Phase 3 and orphan designation status across major regulators, there is a compelling case for regional distribution partnerships, licensing deals, and early access programs in EU, US, and Switzerland.

Manufacturing automation The company’s pursuit of fully automated skin tissue production via denovoCast positions it to engage with life sciences automation providers, contract manufacturers, and facility expansion partners to meet scalable demand.

Regenerative medicine evangelist CUTISS’ TECHBIO platform and expansion into other regenerative applications offer cross-sell opportunities in contract research, consulting services, and collaborations with biopharma and space biology initiatives seeking regenerative solutions.

Funding momentum Recent Series C financing and substantial private/public backing indicate investor confidence and potential for co-investment opportunities, joint grant applications, and accelerated go-to-market collaborations.